{
  "ticker": "IBX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02968080",
  "id": "02968080",
  "pages": 2,
  "price_sensitive": true,
  "date": "20250710",
  "time": "0933",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250710/pdf/06lnt29sx4rjv9.pdf",
  "summary": "- **FDA Feedback**: Received positive formal written feedback from the FDA on Phase 2 HER2 Breast Cancer clinical trial plan.  \n- **Next Steps**: In-person FDA meeting scheduled to finalize review process ahead of IND submission.  \n- **IND Submission Timeline**: Expected in Q3 2025.  \n\n*No capital markets or trading-specific material information identified.*",
  "usage": {
    "prompt_tokens": 851,
    "completion_tokens": 74,
    "total_tokens": 925,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-09T23:49:42.668685"
}